Payment overview · 2025
General Payments
$348.17
16 reported records · 7 companies
Healthcare provider profile · identity verified
Vanh Luangphakdy, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SARASOTA, FL · NPI 1487834172
Verified facts
What the public records show
CMS Open Payments records show Vanh Luangphakdy, MD received $348.17 in general payments during 2025 across 16 reported records.
Exact Sciences Corporation accounted for 31.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Paxlovid, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $108.43 | 31.1% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $88.71 | 25.5% | 6 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $44.60 | 12.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $39.68 | 11.4% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $29.31 | 8.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.55 | 5.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.89 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $348.17 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $76.80 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $72.03 | 5 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $44.60 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $31.63 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $29.31 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 71 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 30 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
111 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
30 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 523 | 146 |
| Atorvastatin Calcium | Atorvastatin Calcium | 502 | 148 |
| Simvastatin | Simvastatin | 495 | 137 |
| Alprazolam | Alprazolam | 378 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 332 | 86 |
| Lisinopril | Lisinopril | 325 | 83 |
| Losartan Potassium | Losartan Potassium | 314 | 96 |
| Omeprazole | Omeprazole | 246 | 72 |
| Metformin Hcl | Metformin Hcl | 239 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 201 | 56 |
| Tramadol Hcl | Tramadol Hcl | 173 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 172 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 162 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 157 | 44 |
| Gabapentin | Gabapentin | 143 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 49 |
| Sertraline Hcl | Sertraline Hcl | 133 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 124 | 34 |
| Trazodone Hcl | Trazodone Hcl | 121 | 24 |
| Eliquis | Apixaban | 111 | 21 |
| Lorazepam | Lorazepam | 109 | 23 |
| Furosemide | Furosemide | 107 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 103 | 26 |
| Ozempic | Semaglutide | 101 | 15 |
| Azithromycin | Azithromycin | 100 | 83 |
| Allopurinol | Allopurinol | 98 | 26 |
| Glipizide Er | Glipizide | 98 | 30 |
| Clonazepam | Clonazepam | 94 | 23 |
| Atenolol | Atenolol | 90 | 25 |
| Alendronate Sodium | Alendronate Sodium | 89 | 23 |
| Temazepam | Temazepam | 85 | 24 |
| Carvedilol | Carvedilol | 79 | 19 |
| Methylprednisolone | Methylprednisolone | 79 | 70 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | 23 |
| Jardiance | Empagliflozin | 71 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 21 |
| Meloxicam | Meloxicam | 69 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 19 |
| Amoxicillin | Amoxicillin | 61 | 53 |
| Ezetimibe | Ezetimibe | 61 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 16 |
| Diazepam | Diazepam | 57 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 57 | 45 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 57 | 22 |
| Glimepiride | Glimepiride | 56 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 56 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 48 |
| Prednisone | Prednisone | 55 | 34 |
| Famotidine | Famotidine | 52 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 52 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 11 |
| Potassium Chloride | Potassium Chloride | 47 | 16 |
| Estradiol | Estradiol | 44 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 34 |
| Glipizide | Glipizide | 41 | suppressed |
| Bupropion Xl | Bupropion Hcl | 40 | 11 |
| Montelukast Sodium | Montelukast Sodium | 40 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 40 | suppressed |
| Finasteride | Finasteride | 38 | 12 |
| Novolog Flexpen | Insulin Aspart | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 20 |
| Gemfibrozil | Gemfibrozil | 35 | 11 |
| Spironolactone | Spironolactone | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Cephalexin | Cephalexin | 32 | 27 |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 14 |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 12 |
| Sucralfate | Sucralfate | 14 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Norethindron-Ethinyl Estradiol | Norethindrone Ac/Eth Estradiol | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $348.17 · 16 records | Exact Sciences Corporation | AIRSUPRA, Cologuard Collection Kit, INJECTAFER, JARDIANCE, MOUNJARO, PAXLOVID, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, WaveWriter Alpha Prime 16, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error